NCT04341493 is a Phase 4 clinical trial of Nitazoxanide 500 MG in Coronavirus Infection, sponsored by Hugo Mendieta Zeron.

Who is sponsoring NCT04341493?

NCT04341493 is sponsored by Hugo Mendieta Zeron.

What drugs are being tested in NCT04341493?

Interventions in NCT04341493: Nitazoxanide 500 MG, Hydroxychloroquine.

What condition does NCT04341493 study?

NCT04341493 studies Coronavirus Infection.

Is NCT04341493 still recruiting?

NCT04341493 is currently terminated. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT04341493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

Terminated Phase 4 Last updated 1 April 2021

What this trial tests

Phase 4 trial testing Nitazoxanide 500 MG in Coronavirus Infection in 44 participants. Terminated before completion.

Timeline

6 April 2020

Primary endpoint
30 August 2020

30 December 2020

Quick facts

Lead sponsor	Hugo Mendieta Zeron
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	44
Start date	6 April 2020
Primary completion	30 August 2020
Estimated completion	30 December 2020
Sites	1 location across Mexico

Drugs / interventions tested

Nitazoxanide 500 MG — full drug profile →
Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →

Conditions studied

Coronavirus Infection — all drugs for Coronavirus Infection →

Sponsor

Hugo Mendieta Zeron — full company profile →

Who can join

5 and older, any sex, with Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronaviruses (CoV) are positive-sense single-stranded RNA viruses that infect a wide range of hosts producing diseases ranging from the common cold to serious / fatal events. Nitazoxanide (NTZx) is a derivative of 5-nitrothiazole, synthesized in 1974 by Rosignol - Cavier. NTZx has powerful antiviral effects through the phosphorylation of protein kinase activated by double-stranded RNA, which leads to an increase in phosphorylated factor 2-alpha, an intracellular protein with antiviral effects. The purpose of this study is to contrast the beneficial effect of NTZx vs NTZx plus hydroxychloroquine in patients Coronavirus Disease (COVID-19) as well as against other treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Nitazoxanide 500 MG

Trials testing the same drug.

NCT06827756 — Comparative Study of Secondary Prophylaxis for SBP · Phase 4 · completed

Other recruiting trials for Coronavirus Infection

Currently open trials in the same condition.

NCT04885504 — Post COVID-19 Biorepository · recruiting
NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04341493 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hugo Mendieta Zeron
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04341493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing